Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.57 |
| ▸ | CBFB | Q13951 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27835033 | 0.83 | CASP6 (0.57) | CASP6CBFBNR4A2ALDH1A1KMT2A | |
| SCHEMBL3584680 | 0.83 | CASP6 (0.57) | CASP6CBFBNR4A2ALDH1A1KMT2A | |
| SCHEMBL24368384 | 0.81 | CASP6 (0.51) | CASP6NR4A2ALDH1A1KMT2ACASP1 | |
| SCHEMBL30174396 | 0.81 | ALDH1A1 (0.46) | CASP6NR4A2ALDH1A1KMT2ACASP1 | |
| SCHEMBL1161458 | 0.81 | ALDH1A1 (0.46) | CASP6NR4A2ALDH1A1KMT2ACASP1 | |
| SCHEMBL1750620 | 0.79 | CASP6 (0.71) | CASP6NR4A2ALDH1A1KMT2ACASP1 | |
| SCHEMBL24368437 | 0.79 | CASP6 (0.53) | CASP6NR4A2ALDH1A1KMT2ACASP1 | |
| SCHEMBL3586679 | 0.79 | CASP6 (0.53) | CASP6NR4A2ALDH1A1KMT2ACASP1 | |
| SCHEMBL11102883 | 0.77 | CASP6 (0.54) | CASP6NR4A2ALDH1A1KMT2ACASP1 | |
| SCHEMBL10368122 | 0.77 | CASP6 (0.62) | CASP6NR4A2ALDH1A1KMT2ACASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102015716-B | Imidazo [1,2-b] pyridazine derivatives for the treatment of C-MET tyrosine kinase mediated disease | NOVARTIS AG | 2014-09-17 | — | — | CN | disclosed |
| US-8822468-B2 | 3-Methyl-imidazo[1,2-b]pyridazine derivatives | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2265614-A1 | IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | NOVARTIS AG | 2009-10-22 | — | — | US | disclosed |
| WO-2009106577-A1 | IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20080214455-A1 | Novel Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| EP-1879563-A4 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1879563-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006132739-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | MET, ERBB2, ALK | CASP6 2629/4885CBFB 2572/4885NR4A2 2353/4885 |
| US-20080214455-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | CASP6 3301/4885CBFB 3307/4885NR4A2 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.